Piper Sandler’s Debt Capital Markets Soar, Advisory Fees to Dip
Piper Sandler’s Q1 saw Debt Capital Markets Advisory revenue surge, while total Advisory fees are set to decline sequentially on slower bank M&A and reduced sponsor urgency. Healthcare equity capital markets delivered outsized share gains, but Technology M&A activity slowed as valuations fell with AI-related caution.
1. Debt Capital Markets Performance
Piper Sandler’s Debt Capital Markets Advisory business was a major bright spot in Q1, reporting significant revenue growth driven by higher transaction volumes and recent private capital advisory deals closed following last year’s acquisition.
2. Advisory Fee Outlook
Overall Advisory fees are expected to decline sequentially as announced bank M&A transactions slowed, particularly among larger deals, and sponsor-driven transactions remain in pitching stages with lower execution urgency.
3. Equity Capital Markets Trends
The firm captured outsized market share in Healthcare equity capital markets thanks to several large fees, although management cautioned that such performance is unlikely to be repeated in Q2 despite an open biotech fundraising environment.
4. Technology M&A Caution
Technology M&A showed relative resilience with a modest uptick from last year, but larger software transactions are constrained by lower valuations and caution around AI-driven disruption, leading to slower deal flow.